Pros | ![]() Larger AUM within category. ![]() Beats FD returns for both 3Y & 5Y duration. | ![]() 3Y returns in the top 25% of the category. ![]() Larger AUM within category. | ||
Cons | ![]() 3Y returns in the bottom 25% of the category. | - |
INDMoney rank | 7/23 | - | ||
Category,Subcateogry | Equity,Global - Other | Equity,Global - Other | ||
Fund Age | 12 Years | 3 Years | ||
Fund Size | 3333 Cr | 2010 Cr | ||
Min Investment | SIP ₹100 Lumpsum ₹5000 | SIP ₹5000 Lumpsum ₹5000 | ||
Expense Ratio | 1.24% | 0.68% | ||
Exit Load | 1% | 0.5% | ||
Benchmark Index | S&P 500 TR USD | NYSE FANG+ TR USD |
No of Holdings | 64 | - | ||
Top 5 Holdings | Gilead Sciences Inc (2.87%) Corteva Inc (2.8%) The Walt Disney Co (2.73%) Bristol-Myers Squibb Co (2.68%) Bio-Rad Laboratories Inc Class A (2.66%) | - | ||
No of Sectors | 9 | - | ||
Top 3 Sectors | Health (27.2%) Industrial (15.63%) Tech (14.86%) | - | ||
Equity % | 98.56% | - | ||
Debt % | - | - | ||
P/E | 24.98 | 41.89 | ||
P/B | 3.39 | 14.3 | ||
Credit Quality | - | - | ||
Modified Duration | - | - | ||
YTM | - | - |
1-Month Return | -2.43% | -6.18% | ||
3-Month Return | -2.35% | 13.51% | ||
6-Month Return | -0.09% | 33.45% | ||
1-Year Return | 10.81% | 51.64% | ||
3-Year Return | 12.6% | 38.74% | ||
5-Year Return | 17.07% | - |
Sharpe | 0.4 | 1.1 | ||
Alpha | -5.3 | 8.53 | ||
Beta | 1.06 | 0.84 | ||
Standard Deviation | 18.39 | 27.99 | ||
Information Ratio | -0.74 | 0.3 |
Description | ICICI Prudential US Bluechip Equity Fund Direct Plan Growth is an equity fund.The fund could potentially beat inflation in the long-run. | Mirae Asset NYSE FANG+ ETF Fund of Fund Direct Growth is an equity fund.The fund could potentially beat inflation in the long-run. | ||
Managers | Ritesh Lunawat | Ekta Gala |